On the basis of these past studies, our research innovatively compared the prognostic impact of all six family members in prostate cancer and found that PRDX5 has the strongest predictive value for poor prognosis in PCa patients and is most closely associated with adverse outcomes. The gene discussed is PRDX5; the disease is posterior cortical atrophy.